• Insitro, an AI biotech company, is laying off 22% of its staff (around 60 people).
• The layoff is attributed to a downturn in biotech fundraising.
• Insitro aims to streamline operations and extend its financial runway into 2027 with this action.

Insitro, a biotech company specializing in artificial intelligence and founded by Daphne Koller, has announced a layoff of 22% of its staff, which translates to roughly 60 employees. This decision comes amidst a challenging period for biotech companies, characterized by reduced fundraising opportunities. Insitro's management indicates that this action is intended to streamline operations, allowing them to concentrate on key priorities and secure the company's financial stability until 2027.

• What: Insitro is laying off 22% of its staff.
• Who: Insitro, Daphne Koller, Insitro spokesperson.
• When: Announced Thursday, May 8, 2025.
• Where: Not specified beyond Insitro as a company.

The layoff at Insitro reflects the broader challenges faced by biotech startups in securing funding. The company's decision to reduce staff and streamline operations is a strategic move to conserve resources and extend its operational runway until 2027. This action indicates a shift towards prioritizing financial stability and focusing on key research areas rather than widespread early-stage research.

This proactive action streamlines our operations, sharpens our focus on key priorities, and extends our runway into 2027.

Insitro's layoff of 22% of its workforce is a strategic response to a challenging funding environment in the biotech sector. The company aims to ensure its long-term viability by streamlining operations and focusing on key priorities, with the goal of extending its financial runway into 2027. The situation reflects the broader pressures on biotech startups to manage resources effectively amidst funding constraints.